As disclosed by the Company in its Current Report on Form 8-K filed on August 23, 2016, in
connection with the consummation of the Merger, the former members of the Companys board of directors were replaced with the individuals listed on Annex A to this Notice.
It is expected that, initially following the Merger, the business and operations of the Company will be continued substantially as they are
currently being conducted. Medtronic is in the process of conducting a comprehensive review of the Companys business, operations, capitalization and management with a view to optimizing development of the Companys potential in
conjunction with Medtronics other businesses. Medtronic will continue to evaluate the business and operations of the Company during the pendency of the Fundamental Change Repurchase Right and will take such actions as it deems appropriate
under the circumstances then existing.
Except as disclosed in this Notice, none of the Company, Medtronic or Parent, or any of their
respective directors or executive officers, currently have any plans, proposals or negotiations that relate to or would result in any of the events described in Item 1006(c) of Regulation M-A issued under the Exchange Act.
8. INTERESTS OF DIRECTORS, EXECUTIVE OFFICERS AND
AFFILIATES OF THE COMPANY IN THE NOTES.
Based on a reasonable inquiry by Parent:
||none of the Company, Medtronic or Parent, or any executive officer or director of the Company, Medtronic or Parent or any associate (as such term is defined in Rule 12b-2 under the Exchange Act) of the
foregoing persons has any beneficial interest in the Notes; and |
||during the 60 days preceding the date of this Notice, none of such persons engaged in any transactions in the Notes, other than the transactions required by the applicable Indenture described herein. |
The Company will not repurchase any Notes from any officer, director or affiliate of the Company. A list of the directors and executive
officers of the Company is attached to this Notice as Annex A.
9. AGREEMENTS INVOLVING THE
Based on a reasonable inquiry by Parent, except for, and as
contemplated by, the Merger Agreement and as otherwise described in this Notice, none of the Company, Medtronic or Parent, or any of their respective directors or executive officers, is a party to any agreement, arrangement or understanding with any
other person with respect to any securities of the Company, including, but not limited to, any agreement, arrangement or understanding concerning the transfer or the voting of any securities of the Company, joint ventures, loan or option
arrangements, puts or calls, guarantees of loans, guarantees against loss or the giving or withholding of proxies, consents or authorizations.
PURCHASES OF NOTES BY THE COMPANY AND ITS AFFILIATES.
Each of the Company and its affiliates, including their executive officers and directors, is prohibited under applicable United States federal
securities laws from purchasing Notes (or the right to purchase Notes), other than through the Fundamental Change Repurchase Right or a call or redemption of the Notes in accordance with their terms and conditions, from the date of this Notice until
at least the tenth business day after the Fundamental Change Repurchase Date. Following such time, if any Notes remain outstanding, the Company and its affiliates may purchase Notes in the open market, in private transactions, through a
subsequent tender offer or otherwise, any of which may be consummated at repurchase prices higher or lower than the Fundamental Change Repurchase Price. Any decision to purchase Notes after the Fundamental Change Repurchase Date, if any, will depend
upon many factors, including the market price of the Notes, the amount of Notes validly surrendered for repurchase pursuant to the Fundamental Change Repurchase Right and not validly withdrawn, the business and financial position of the Company and
general economic and market conditions.